Yu et al. have shown that the overactivation of the PI3K/Akt pathway is a hallmark of human malignancies, and PI3K inhibitors such as copanlisib, alpelisib, idelalisib, duvelisib, and umbralisib have been approved by the FDA for the treatment of various tumor diseases [32]. Here, AKT1 is linked to neoplasm.